Emory's Angela Haynes-Ferere and Cedars-Sinai's Amanda Velazquez say plateaus are common and advise seeing a doctor rather than stopping the drug.
Recap by typeshit. Full story at health.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Amgen shares are up about 24% this year on interest in its obesity candidate MariTide. One bearish take flags manufacturing scale and a crowded GLP-1 market.
In a new suit, Frank Campbell Jr. claims he developed gastroparesis after starting the drugs, leaving him with debilitating nausea, vomiting and abdominal pain.
Loading…